Request Demo
Vertex pays $4.9 billion to hike Alpine’s immunology trail
AcquisitionDrug ApprovalImmunotherapyPhase 2
Vertex's $4.9 billion purchase of Alpine Immune Sciences is the largest biopharma acquisition of the year thus far.
Vertex Pharmaceuticals is buying AAlpine Immune Sciencesfor $4.9 billion, the companies announced Wednesday afternoon.
Vertex Pharmaceuticalssition so fAlpine Immune Sciencesring the immense investments that immunology and inflammation have drawn from biopharmas. Gilead’s $4.4 billion purchase of liver disease biotech CymaBay was the largest M&A deal before Thursday. And a week ago, Genmab made it's largest-ever buy, scooping up cancer drug developer ProfoundBio.
Vertex is set to get ahold of Alpine’s lead asset, povetacicept, a dual B cell cytokine agonist that Alpinflammation best-in-class potential as aGileadment for IgA nephropathy (Igliver diseaseCymaBayGenmabcancerProfoundBio
New data from an open-label basket trial released Tpovetaciceptd that poB cell cytokine agonistB cell cytokineen at 80mg once every four weeks, spurred a 64.1% reduction in proteinuriIgA nephropathy (IgAN)r kidney filtration. Alpine plans to launch a phase 3 trial for patients with the indication in the second half of the year and is also testing the drug in patients with lupus and autoimmune cytopenias.
Meanwhile, also in IgAN, Novartis is working on several assets, includpovetacicept and atrasentan, which the Swiss pharma obtained from its $3.2 billiproteinuriaion o Chinook Therapeutics last year. Calliditas Therapeutics in December gained a full FDA approval for Tarpeyo, a formulation of budesonide, in IgAN.lupusautoimmune cytopenias
The Alpine acquisitIgANboNovartisertex’s standing in the immunology space Fabhalta pharatrasentano stand out. Johnson & Johnson CEO Joaquin Duato told investors in FebChinook Therapeuticspportunity fCalliditas Therapeuticseas like neuroscience and iFDAnology, and TaTarpeyompleted its $4 billbudesonidese ofIgANubs’ TYK2 candidate back in February 2023. Other pharmas, like AbbVie, Bristol Myers Squibb and Sanofi, have doubled down on investing in immunology.
Vertex CEO Reshma Kewalramani, MVertexaid in a statement that she and the Vertex team look forward to explorinJohnson & Johnsonpotential as a “‘pipeline-in-a-product'”.TakedaTYK2AbbVieBristol Myers SquibbSanofi
Vertexcicept’s profile has ascended within Alpine’s pipeline as delays andVertexuctured agreements marked the repovetacicept of AbbVie-partnered, acazicolcept. Alpine announced in late 2023 that the two had restructured their 2020 deal, with Alpine agreeing to stop the study early and accept a reduced option fee if AbbVie decided to opt into the asset. Alpine previously disclosed that phase 2 costs had exceeded expectations.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Indications
Targets
Drugs
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.